ReviewThe efficacy of novel B cell biologics as the future of SLE treatment: A review
Introduction
SLE is a relapsing and remitting, chronic autoimmune inflammatory disease with wide ranging multi-systemic effects. Clinical features develop through autoantibody formation, immune complex deposition and cytokine activation. Symptoms vary from general malaise, fever, lethargy and depression to more severe musculoskeletal, cutaneous, pulmonary, renal, haematopoietic, cardiac and nervous system manifestations [1]. (See Fig. 1, Fig. 2.)
African–American (AA) women are the highest risk sub-population affected by SLE with 1 in 500 people affected [2]. 80% of patients are females of childbearing age, with males 9 times less likely to develop SLE [2], [3]. Klinefelter's syndrome (47 XXY) patients, as well as SLE females on hormone replacement therapy have been shown to have an increased risk of relapsing lupus — together suggesting an aetiological role for oestrogen [4], [5]. Hereditary factors (40% rate of concordance seen in monozygotic twins), environmental trigger factors (Epstein–Barr virus, UV light and drug interventions such as isoniazid, penicillamine and hydralazine) as well as genetic influences (approximately 200 different genetic loci coding for HLA variants and complement deficiencies have been described) also play a complex multifactorial role in the aetiology of SLE [6], [7], [8], [9].
Section snippets
Pathogenesis
Following triggers such as EBV infection or UV radiation, inherent abnormalities in the innate and adaptive immune systems result in the collection of ineffectively cleared apoptotic nuclear fragments. These include double and single stranded DNAs (dsDNA, ssDNA), RNA binding nuclear antigens (Ro, La and Smith antigens) and non-nuclear fragments, which are then processed by Antigen Presenting Cells (APCs) such as B cells or plasmacytoid dendritic cells (pDCs) [10]. Self-antigens are presented on
Therapeutics in SLE: current and future medications
The existing standard of care for SLE depends primarily on disease severity and has been in place for over 60 years. NSAIDS (Aspirin, Ibuprofen and Diclofenac) and anti-malarials (hydroxychloroquine) are used in mild disease. Corticosteroids are vital in moderate–severe disease with additional immunosuppressives such as Mycophenolate mofetil (MMF), Azathioprine (AZT), Cyclophosphamide and Cyclosporine effective in severe cases of SLE [15].
The efficacy of current SLE medication has been
Anti-CD20: Rituximab
CD20 is a surface antigen expressed throughout B cell maturation and is involved in B cell activation by aiding Ca2 + influx [19]. CD20 is not expressed on haematopoietic lymphoid stem cells or pre-B cells and is lost upon terminal differentiation into plasma B cells — thus antagonism would not prevent B cell regeneration [20].
Rituximab is an anti-CD20 human-murine monoclonal chimeric antibody that causes selective short-term depletion of matured B cells through three mechanisms: induction of
B lymphocyte stimulator (BLyS) & A proliferation inducing ligand (APRIL)
Two of the key B cell stimulatory cytokines include components of the TNF ligand superfamily, member 13 or APRIL and member 13b or BLyS (B cell activating factor, BAFF) [18].
Several studies have deduced the vital role of BLyS in B cell survival, proliferation and antibody secretion, through actions upon three main receptors: the transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI), the BLyS receptor (BAFF-R) and the B cell maturation antigen (BCMA). APRIL, a
Cost effectiveness
The cost burden of SLE morbidity was recently assessed in the UK amongst 86 lupus patients with a mean SLEDAI score of 7.7 [60]. The mean total cost for severe and non-severe lupus patients was £4652 and £2105 per year respectively (p < 0.001). For both groups, immunosuppressive therapies accounted for the majority of the cost, £1187 (25.5%) and £523 (24.8%) (p = 0.003), whereas biological therapies cost £532 (11.4%) and £109 (5.2%) for severe and non-severe groups respectively (p = 0.007). These
Conclusion
Recent advances in SLE research have begun to deduce the intricate pathogenesis underlying this autoimmune condition highlighting the critical role of auto-B cells in autoantibody formation, antigen presentation and T cell interaction. Standard of care therapy drawbacks has initiated the quest for SLE disease pathway specific biologics to ameliorate the condition with minimal side effects.
In 2011 the FDA signified a new direction for SLE by approving Belimumab as the first novel therapy for
Take Home Messages
- •
Standard of care therapies produces adverse side effects through untargeted actions.
- •
B cell biologics are an attractive therapeutic option specific to SLE pathogenesis.
- •
Early phase trials have been successful and Belimumab has been FDA approved.
- •
Other B cell depletion and anti-cytokine treatments are under Phase III assessment.
- •
Different subpopulations and manifestations may respond differently to treatment.
Conflict of Interest
There are no conflicts of interest to declare and no funding or grants have been received for this research.
Acknowledgements
None.
References (61)
Mechanisms of disease for the clinician: systemic lupus erythematosus
Ann Allergy Asthma Immunol
(2013)- et al.
Emerging and critical issues in the pathogenesis of lupus
Autoimmun Rev
(2013) - et al.
Clinical applications of anti-CD20 antibodies
J Lab Clin Med
(1999) - et al.
Administration of adenovirus encoding anti-CD20 antibody gene induces B-cell deletion and alleviates lupus in the BWF1 mouse model
Int Immunopharmacol
(2011) - et al.
Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events
Autoimmun Rev
(2011) - et al.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Lancet
(2011) - et al.
Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies
Best Pract Res Clin Rheumatol
(2009) - et al.
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2
Immunity
(2002) - et al.
The DWEYS peptide in systemic lupus erythematosus
Trends Mol Med
(2012) - et al.
Belimumab: targeted therapy for lupus
Int J Rheum Dis
(2013)
The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus
Climacteric
Klinefelter's syndrome (47, XXY) among men with systemic lupus erythematosus
Acta Paediatr
Review Epstein–Barr virus and systemic lupus erythematosus
Curr Opin Rheumatol
Genetics of systemic lupus erythematosus
Future Rheumatol
The genetics of systemic lupus erythematosus and implications for targeted therapy
Ann Rheum Dis
Lupus nephritis. How latest insights into its pathogenesis promote novel therapies
Curr Opin Rheumatol
B-cell-targeted therapies in systemic lupus erythematosus
Cell Mol Immunol
The role of B cells in lpr/lpr-induced autoimmunity
J Exp Med
A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice
J Immunol
Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo
J Am Soc Nephrol
A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus
J Exp Med
Pharmacotherapy of systemic lupus erythematosus
Expert Opin Pharmacother
Systemic lupus erythematosus: an update on current pharmacotherapy and future directions
Expert Opin Biol Ther
The immunological basis of B-cell therapy in systemic lupus erythematosus
Int J Rheum Dis
B-cell depletion in the treatment of lupus nephritis
Nat Rev Nephrol
Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2 + conductance found constitutively in B lymphocytes
J Cell Biol
Novel biological treatments for systemic lupus erythematosus: current and future modalities
Isr Med Assoc J
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients
Rheumatology (Oxford)
Long term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus
J Rheumatol
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab
Arthritis Rheum
Cited by (97)
Relative CTLA-4, PTPN-22, and interleukin 37 mRNA expressions in patients with lupus nephritis
2023, Reumatologia ClinicaBacteroides fragilis alleviates the symptoms of lupus nephritis via regulating CD1d and CD86 expressions in B cells
2020, European Journal of PharmacologyPost-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
2020, Autoimmunity ReviewsCurrent Insights Into Systemic Lupus Erythematosus: From Pathogenesis to Biomarkers and Therapeutical Strategies
2019, Mosaic of Autoimmunity: The Novel Factors of Autoimmune DiseasesCytokines as therapeutic targets in primary Sjögren syndrome
2018, Pharmacology and Therapeutics